<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Musculoskelet Disord</journal-id><journal-title>BMC Musculoskeletal Disorders</journal-title><issn pub-type="epub">1471-2474</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19118498</article-id><article-id pub-id-type="pmc">2642755</article-id><article-id pub-id-type="publisher-id">1471-2474-10-1</article-id><article-id pub-id-type="doi">10.1186/1471-2474-10-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Bone mass in schizophrenia and normal populations across different decades of life</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Renn</surname><given-names>Jenn-Huei</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>johnrenn@ms13.hinet.net</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Yang</surname><given-names>Nan-Ping</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>g880703@ym.edu.tw</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Chueh</surname><given-names>Ching-Mo</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>chingmochueh@yahoo.com.tw</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Lin</surname><given-names>Chih-Yuan</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>psy211.lin@msa.hinet.net</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Lan</surname><given-names>Tsuo-Hung</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><xref ref-type="aff" rid="I7">7</xref><email>tosafish@ms73.hinet.net</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Chou</surname><given-names>Pesus</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pschou@ym.edu.tw</email></contrib></contrib-group><aff id="I1"><label>1</label>Community Medicine Research Center and Institute of Public Health, National Yang-Ming University, Taipei, ROC</aff><aff id="I2"><label>2</label>Yuli Veterans Hospital, Veterans' Affairs Commission, Executive Yuan, Hualien, Taiwan, ROC</aff><aff id="I3"><label>3</label>Department of Geriatrics and Orthopedic Surgery, Tao-Yuan General Hospital, DOH, Executive Yuan, Tao-Yuan, Taiwan, ROC</aff><aff id="I4"><label>4</label>Department of Psychiatry, Kuang Tien General Hospital, Taichung, Taiwan, ROC</aff><aff id="I5"><label>5</label>Department of Psychiatry, Yang-Ming University, Taipei, Taiwan</aff><aff id="I6"><label>6</label>Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan</aff><aff id="I7"><label>7</label>Division of Mental Health &#x00026; Substance Abuse, National Health Research Institute, Zhunan, Taiwan</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>1</day><month>1</month><year>2009</year></pub-date><volume>10</volume><fpage>1</fpage><lpage>1</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2474/10/1"/><history><date date-type="received"><day>14</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>1</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Renn et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Renn et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>               Renn               Jenn-Huei                                             johnrenn@ms13.hinet.net            </dc:author><dc:title>            Bone mass in schizophrenia and normal populations across different decades of life         </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Musculoskeletal Disorders 10(1): 1-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2474(2009)10:1&#x0003c;1&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2474</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Chronic schizophrenic patients have been reported as having higher osteoporosis prevalence. Survey the bone mass among schizophrenic patients and compare with that of the local community population and reported data of the same country to figure out the distribution of bone mass among schizophrenic patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>965 schizophrenic patients aged 20 years and over in Yuli Veterans Hospital and 405 members aged 20 and over of the community living in the same town as the institute received bone mass examination by a heel qualitative ultrasound (QUS) device. Bone mass distribution was stratified to analyzed and compared with community population.</p></sec><sec><title>Results</title><p>Schizophrenic patients have lower bone mass while they are young. But aging effect on bone mass cannot be seen. Accelerated bone mass loss during menopausal transition was not observed in the female schizophrenic patients as in the subjects of the community female population.</p></sec><sec><title>Conclusion</title><p>Schizophrenic patients have lower bone mass than community population since they are young. Further study to investigate the pathophysiological process is necessary to delay or avoid the lower bone mass in schizophrenia patients.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Osteoporosis is a bone disease that can reduce both bone mass and bone strength. It is typically thought to be age-related [<xref ref-type="bibr" rid="B1">1</xref>] and can cause serious bone fractures that can have significant and even devastating physical, psychological and financial consequences for patients and their families [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. The prevalence of schizophrenia is about 1% worldwide. Rigotti and colleagues[<xref ref-type="bibr" rid="B5">5</xref>] first reported decreased bone density in patients with a confirmed mental disorder as anorexia nervosa. Other researchers have reported similar findings in anorexia [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. Osteoporosis was also reported in schizophrenia[<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>] patient and the prevalence of non-traumatic fractures in chronic schizophrenic patients has been reported to be about 25% in a cross-sectional survey[<xref ref-type="bibr" rid="B10">10</xref>]. A prevalence of osteoporosis in chronic schizophrenic patients has been reported, but a study of the prevalence of osteoporosis in chronic schizophrenic patients on a large population has not previously been reported. In this study, 965 chronic in-patient schizophrenic cases in Yuli Veterans hospital of Yuli town in Taiwan were surveyed; 405 members of the community population were also surveyed as the control group simultaneously. The bone mass distribution in the chronic schizophrenic patients was evaluated and compared with that of the community population subjects.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Population</title><p>The present study included 965 patients, who were older than 20 years old, chronic schizophrenia admitted to the Psychiatric Department of Yuli Veterans Hospital in Taiwan, ROC, between 2003 and 2004. All of these patients met the DSM-IV criteria for schizophrenia as diagnosed by psychiatrists in Yuli Veterans Hospital. Patients with severe extra-pyramidal symptoms (EPS), poor disease control, or severe debility that precluded cooperation with the bone density survey were excluded from the study. For comparison, 405 community members, who were older than 20 years old, living in the same district as Yuli Veterans Hospital, also entered the study. All residents who lived in this district were visited at their home. Those who were not living in Yuli Town during the survey period or did not give consent or had medical or mental disability that prevented them from completing the examination were excluded. The study was approved by the medical ethics policy of the Institutional Review Board Committee at Yuli Veterans Hospital (serial No. 92-11-02A).</p></sec><sec><title>Bone Mass and Quantitative Ultrasound</title><p>A QUS-II Calcaneal Ultrasonometer (Metra Biosystems, Mountain View, CA, USA) was used to measure bone density as broadband ultrasound attenuation (BUA) data. Ultrasound bone densiometry is reported to correlate well with the results of DXA and can predict osteoporosis-related fracture[<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>] or detect bone fragility [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. But there are many authors who question the precision of peripheral bone mineral density. Some authors reported that QUS parameters couldn't be used to predict osteopenia and that the sensitivities and specificities of QUS parameters were not high enough to be used as an alternative method of dual-energy x-ray absorptiometry (DXA) [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. DXA is gold standard for measuring BMD is currently[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. However, DXA scans are time-consuming, costly and expose the patient to radiation, which makes it a less-than-ideal method for a large population survey. On the contrary, a calcaneal ultrasonometer is timesaving, portable and suitable method for large surveys. For this reason, we chose to use it in this study.</p><p>Osteoporosis is defined by decreased bone mineral density (BMD) to a level of or less than -2.5 SD of the mean value of young adults. Firstly, our group assessed the precision of the quantitative ultrasound densitometry. Intra-test precision was calculated from three repeated scans with repositioning in 25 volunteers; the short-term coefficient of variation was 3.5% for BUA. T-scores used in our data were calculated from measured BUA data, the apparatus' specific threshold and further adjustment using data from Chinese patients living in Taiwan as reported by N.P. Yang[<xref ref-type="bibr" rid="B22">22</xref>]. Low bone mass was defined by a T-score of less than -1.0, and severe low bone mass was defined by a T-score of -2.5 or lower in this study. Weight and height data were also measured and collected.</p></sec><sec><title>Statistical Analysis</title><p>All subjects were classified into two subject groups. Admitted schizophrenic patients were classified as schizophrenic patient group. Residents lived in the community were classified as community population group. All the subjects were classified into 5 age groups in decades of age from 20 to 60 years old and 60 years above. Correlation between measured BUA value and weight, gender, subject groups, and age groups was tested by fractional factorial generalized linear model. Interactions between age groups and subject groups were also tested in the same model. Effects of weight, gender and age groups on the differences of means of measured BUA value was tested with generalized linear model in each subject group. Trends of mean BUA values between age groups stratified by subject groups and gender was tested by nonparametric test for trend. Prevalence of osteoporosis data were stratified by both gender and age groups for both groups and reported by descriptive analysis and was compared further with the prevalence reported in Taiwan. All statistical calculations were conducted using the Stata 10/SE system for Mac.</p></sec></sec><sec><title>Results</title><p>The demographic data and BUA value results stratified by subject groups, age groups and gender are presented in Table <xref ref-type="table" rid="T1">1</xref>. There were 623 (65%) male and 342 (35%) female patients in the schizophrenic patient group. Mean age was 47.6 &#x000b1; 15.9 (range 21&#x02013;95) years in the male patients and 46.8 &#x000b1; 11.2 (range 20&#x02013;78) years in the female patients. In the community population group, there were 183 (45%) male and 222 (55%) female subjects; mean age was 60.0 &#x000b1; 18.2 (range 20&#x02013;89) years in male and 54.2 &#x000b1; 16.0 (range 20&#x02013;88) years in the female.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>The Basic Characteristics of the Schizophrenic Patients compared to community population, sampled from the same community, Yu-Li area, Taiwan</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Age Strata (y/o)</td><td align="center" colspan="2"><underline>Studied Subjects</underline></td><td align="center" colspan="2"><underline>BUA (dB/MHz)</underline></td><td align="center" colspan="2"><underline>Weight (Kgw)</underline></td></tr><tr><td></td><td align="left">Schizophrenic</td><td align="left">Community</td><td align="left">Schizophrenic</td><td align="left">Community</td><td align="left">Schizophrenic</td><td align="left">Community</td></tr><tr><td></td><td align="left">No.(%)</td><td align="left">No.(%)</td><td align="left">Mean (S.D.)</td><td align="left">Mean (S.D.)</td><td align="left">Mean (S.D.)</td><td align="left">Mean (S.D.)</td></tr></thead><tbody><tr><td align="left">Male</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">20&#x02013;29</td><td align="left">59(9.5)</td><td align="left">12(6.6)</td><td align="left">77.1(15.3)</td><td align="left">86.1(21.6)</td><td align="left">69.3(13.9)</td><td align="left">63.9(8.9)</td></tr><tr><td align="left">30&#x02013;39</td><td align="left">184(29.5)</td><td align="left">18(9.8)</td><td align="left">82.3(17.0)</td><td align="left">90.1(17.2)</td><td align="left">71.3(19.2)</td><td align="left">71.3(10.5)</td></tr><tr><td align="left">40&#x02013;49</td><td align="left">177(28.4)</td><td align="left">30(16.4)</td><td align="left">83.9(18.6)</td><td align="left">92.0(19.4)</td><td align="left">67.2(15.3)</td><td align="left">69.5(10.9)</td></tr><tr><td align="left">50&#x02013;59</td><td align="left">77(12.4)</td><td align="left">28(15.3)</td><td align="left">80.3(18.2)</td><td align="left">83.7(20.7)</td><td align="left">67.4(13.4)</td><td align="left">67.3(8.3)</td></tr><tr><td align="left">60 or more</td><td align="left">126(20.2)</td><td align="left">95(51.9)</td><td align="left">82.2(18.2)</td><td align="left">78.0(21.1)</td><td align="left">52.9(9.2)</td><td align="left">66.8(10.9)</td></tr><tr><td align="left">Total</td><td align="right">623</td><td align="right">183</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Female</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">20&#x02013;29</td><td align="left">22(6.4)</td><td align="left">16(7.2)</td><td align="left">71.9(26.5)</td><td align="left">85.3(11.1)</td><td align="left">69.6(12.3)</td><td align="left">53.7(7.7)</td></tr><tr><td align="left">30&#x02013;39</td><td align="left">84(24.6)</td><td align="left">33(14.9)</td><td align="left">76.9(20.8)</td><td align="left">85.8(11.7)</td><td align="left">70.2(15.6)</td><td align="left">57.3(9.9)</td></tr><tr><td align="left">40&#x02013;49</td><td align="left">97(28.4)</td><td align="left">38(17.1)</td><td align="left">81.2(20.5)</td><td align="left">86.3(16.9)</td><td align="left">71.9(19.1)</td><td align="left">59.8(10.7)</td></tr><tr><td align="left">50&#x02013;59</td><td align="left">97(28.4)</td><td align="left">45(20.3)</td><td align="left">82.3(20.1)</td><td align="left">72.0(16.5)</td><td align="left">68.4(7.8)</td><td align="left">58.0(9.2)</td></tr><tr><td align="left">60 or more</td><td align="left">42(12.3)</td><td align="left">90(40.5)</td><td align="left">79.0(19.9)</td><td align="left">68.7(17.1)</td><td align="left">65.3(6.2)</td><td align="left">57.5(10.2)</td></tr><tr><td align="left">Total</td><td align="right">342</td><td align="right">222</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Totally</bold></td><td align="right">965</td><td align="right">405</td><td></td><td></td><td></td><td></td></tr></tbody></table></table-wrap><p>Mean BUA values were lower for male schizophrenic patients as compared with male community population group of same age groups if they were 60 years old or younger. But mean BUA value was higher for male schizophrenic patients in the age group older than 60 years. Mean BUA values were also lower for female schizophrenic patients as compared with female community population group of same age groups if they were younger than 50 years old. But mean BUA values for female schizophrenic patients were higher in age groups older than 50 years. This is demonstrated in Fig. <xref ref-type="fig" rid="F1">1</xref>. A significant trend of mean BUA value with aging was observed in males (p = 0.001) and females (p &#x0003c; 0.001) of community population. It is insignificant in male and female schizophrenic patients group.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>BUA vs. age with 95% confidence and fit line by subject population and sex</bold>.</p></caption><graphic xlink:href="1471-2474-10-1-1"/></fig><p>The male schizophrenic patient group has a higher mean weight than the male community population group except in the age group 40&#x02013;50 and the age group &#x0003e; 60 years old. The mean weight of the female schizophrenic patient group is higher than the female community population group across all age groups.</p><p>Table <xref ref-type="table" rid="T2">2</xref> shows the fractional factorial generalized linear model result of subject groups, gender, weight, and age groups on BUA. The BUA value of females is significant lower than that of males (p &#x0003c; 0.001). Lean subjects have a significantly lower BUA value (p &#x0003c; 0.001). The schizophrenic patient group has a significantly lower BUA value (p &#x0003c; 0.01). Significant effect is seen in the age groups 20&#x02013;29 (p &#x0003c; 0.001), 30&#x02013;39 (p &#x0003c; 0.01) and 40&#x02013;49 (p &#x0003c; 0.05) years old on BUA value. Significant interaction can be seen between subject groups and age group 50&#x02013;59 and age group &#x0003e; 60 years old.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Comparison of BUA in schizophrenic patient and community population group stratified by age group, gender by fractional factorial generalized linear model</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3">(dependent variable = BUA)</td></tr><tr><td align="left">Independent variables</td><td align="right">coef.</td><td align="right">std. err.</td><td align="center">p-value</td></tr></thead><tbody><tr><td align="left">Gender (female vs. male)</td><td align="right">-4.251</td><td align="right">1.054</td><td align="center">***</td></tr><tr><td align="left">Weight (kgw)</td><td align="right">0.158</td><td align="right">0.036</td><td align="center">***</td></tr><tr><td align="left">Group<sup>#</sup>(community vs. schizophrenic)</td><td align="right">13.069</td><td align="right">4.096</td><td align="center">**</td></tr><tr><td align="left">Age group 20&#x02013;39</td><td align="right">-23.949</td><td align="right">6.497</td><td align="center">***</td></tr><tr><td align="left">Age group 30&#x02013;39</td><td align="right">-15.424</td><td align="right">4.980</td><td align="center">**</td></tr><tr><td align="left">Age group 40&#x02013;49</td><td align="right">-10.727</td><td align="right">4.777</td><td align="center">*</td></tr><tr><td align="left">Age group 50&#x02013;59</td><td align="right">-----</td><td align="right">-----</td><td align="center">n.s.</td></tr><tr><td align="left">Age group &#x02267; 60</td><td align="right">-----</td><td align="right">-----</td><td align="center">n.s.</td></tr><tr><td align="left">Group*Age group 20&#x02013;39</td><td align="right">-----</td><td align="right">-----</td><td align="center">n.s.</td></tr><tr><td align="left">Group*Age group 30&#x02013;39</td><td align="right">-----</td><td align="right">-----</td><td align="center">n.s.</td></tr><tr><td align="left">Group*Age group 40&#x02013;49</td><td align="right">-----</td><td align="right">-----</td><td align="center">n.s.</td></tr><tr><td align="left">Group*Age group 50&#x02013;59</td><td align="right">-16.723</td><td align="right">4.826</td><td align="center">**</td></tr><tr><td align="left">Group*Age group &#x02267; 60</td><td align="right">-20.967</td><td align="right">4.563</td><td align="center">***</td></tr><tr><td align="left">Constant</td><td align="right">80.987</td><td align="right">4.741</td><td align="center">***</td></tr></tbody></table><table-wrap-foot><p>n.s. : not significant</p><p>* : p &#x0003c; 0.05</p><p>** : p &#x0003c; 0.01</p><p>*** : p &#x0003c; 0.001</p><p>#: schizophrenic patient group and community population group</p></table-wrap-foot></table-wrap><p>Generalized linear model was used to test the effect of gender, weight, and age on the difference of mean BUA value and was stratified by subject groups. The result is shown in Table <xref ref-type="table" rid="T3">3</xref>. Males have significantly higher mean BUA value than females in both schizophrenic patient and community population groups (p &#x0003c; 0.05). Higher BUA value can be significantly seen in heavier subjects in both subject groups (p &#x0003c; 0.05 in schizophrenic patient group, and p &#x0003c; 0.001 in community population group). In the community population group, the coefficient of age is negative and is significant (p &#x0003c; 0.001). But the coefficient of age is positive and is significant also (p &#x0003c; 0.05) in the schizophrenia patient group. Interaction is tested also between age and weight and is insignificant.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Comparison of BUA by gender, weight, and age in schizophrenic patient and community population group with generalized linear model</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3">Schizophrenic patient</td><td align="center" colspan="3">Community population</td></tr></thead><tbody><tr><td align="left">Independent variable</td><td align="right">&#x003b2;</td><td align="right">std. err.</td><td align="center">p-value</td><td align="right">&#x003b2;</td><td align="right">std. err.</td><td align="center">p-value</td></tr><tr><td align="left">Gender (male vs female)</td><td align="right">-2.731</td><td align="right">1.278</td><td align="center">*</td><td align="right">-4.474</td><td align="right">1.986</td><td align="center">*</td></tr><tr><td align="left">Weight (kgw)</td><td align="right">0.105</td><td align="right">0.041</td><td align="center">*</td><td align="right">0.445</td><td align="right">0.086</td><td align="center">***</td></tr><tr><td align="left">Age (years)</td><td align="right">0.097</td><td align="right">0.044</td><td align="center">*</td><td align="right">-0.362</td><td align="right">0.052</td><td align="center">***</td></tr><tr><td align="left">Constant</td><td align="right">73.189</td><td align="right">4.218</td><td align="center">***</td><td align="right">78.992</td><td align="right">8.206</td><td align="center">***</td></tr></tbody></table><table-wrap-foot><p> * : p&#x0003c;0.05</p><p>** : p&#x0003c;0.01</p><p> *** : p&#x0003c;0.001</p></table-wrap-foot></table-wrap><p>Table <xref ref-type="table" rid="T4">4</xref> shows the comparison of prevalence of low bone mass (t-score &#x0003c;-1 computed from BUA value) and severe low bone mass (t-score &#x02266; -2.5 computed from BUA value) between schizophrenic patient group, community population group and surveyed data in Kinmen, Taiwan[<xref ref-type="bibr" rid="B22">22</xref>]. The prevalence of low bone mass and severe low bone mass is both higher in schizophrenic patients in age group 20&#x02013;29 and age 30&#x02013;39 years old. In age groups 40&#x02013;49, 50&#x02013;59 and &#x0003e; 60 years old, the prevalence of low bone mass and severe low bone mass of schizophrenic is also higher than the community population group and the surveyed data in Kinmen, Taiwan.</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Comparison of low bone mass condition between the comminuty population and a schizophrenic population in Taiwanese</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3"><underline>prevalence of low bone mass [t &#x0003c; 1.0]</underline></td><td align="center" colspan="3"><underline>prevalence of severe low bone mass [t &#x02266; -2.5]</underline></td></tr><tr><td></td><td align="left">Schizophrenic population in Yuli area</td><td align="left">Community population in Yuli area</td><td align="left">Community-surveyed People in Kinmen, Taiwan, 2000&#x02013;2003&#x000a7;</td><td align="left">Schizophrenic population in Yuli area</td><td align="left">Community people in Yuli area</td><td align="left">Community-surveyed People in Kinmen, Taiwan, 2000&#x02013;2003&#x000a7;</td></tr><tr><td></td><td align="left">(%)</td><td align="left">(%)</td><td align="left">(%)</td><td align="left">(%)</td><td align="left">(%)</td><td align="left">(%)</td></tr></thead><tbody><tr><td align="left">Age Strata</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Male</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">20&#x02013;29 y/o</td><td align="left">54.2</td><td align="left">50.0</td><td align="left">-----</td><td align="left">15.3</td><td align="left">0</td><td align="left">-----</td></tr><tr><td align="left">30&#x02013;39 y/o</td><td align="left">42.9</td><td align="left">33.3</td><td align="left">-----</td><td align="left">9.8</td><td align="left">0</td><td align="left">-----</td></tr><tr><td align="left">40&#x02013;49 y/o</td><td align="left">37.3</td><td align="left">33.3</td><td align="left">35.5</td><td align="left">6.8</td><td align="left">3.3</td><td align="left">3.9</td></tr><tr><td align="left">50&#x02013;59 y/o</td><td align="left">46.8</td><td align="left">50.0</td><td align="left">42.5</td><td align="left">13.0</td><td align="left">10.7</td><td align="left">7.1</td></tr><tr><td align="left">&#x0003e; 60 y/o</td><td align="left">48.4</td><td align="left">55.8</td><td align="left">55.8</td><td align="left">6.4</td><td align="left">25.3</td><td align="left">16.9</td></tr><tr><td align="left">Female</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">20&#x02013;29 y/o</td><td align="left">77.3</td><td align="left">18.8</td><td align="left">-----</td><td align="left">50.0</td><td align="left">0</td><td align="left">-----</td></tr><tr><td align="left">30&#x02013;39 y/o</td><td align="left">50.0</td><td align="left">18.2</td><td align="left">-----</td><td align="left">26.2</td><td align="left">0</td><td align="left">-----</td></tr><tr><td align="left">40&#x02013;49 y/o</td><td align="left">42.3</td><td align="left">31.6</td><td align="left">38.4</td><td align="left">17.5</td><td align="left">5.3</td><td align="left">6.7</td></tr><tr><td align="left">50&#x02013;59 y/o</td><td align="left">46.4</td><td align="left">68.9</td><td align="left">52.9</td><td align="left">14.4</td><td align="left">28.9</td><td align="left">16.5</td></tr><tr><td align="left">&#x0003e; 60 y/o</td><td align="left">52.4</td><td align="left">78.9</td><td align="left">84.1</td><td align="left">19.1</td><td align="left">31.1</td><td align="left">50.9</td></tr></tbody></table><table-wrap-foot><p>Note: The above three population were screened for low bone mass using the same ultrasonography, QUS-II. The t-score was calculated using machine BUA value and adjusted as: (BUA<sub>individual </sub>&#x02013; 92.72)/13.36 for the male, and (BUA<sub>individual </sub>&#x02013; 87.90)/10.68 for the female. Those were based on the published reference&#x000a7;.</p><p>&#x000a7;Nan-Ping Yang, Shao-Yuan Chuang, Shui-Hu Chen, Pesus Chou. Screening for low bone mass with quantitative ultrasonography in a community without dual X-ray absorptiometry: population-based study. BMC Musculoskeletal Disorders 2006;7:24.</p></table-wrap-foot></table-wrap></sec><sec><title>Discussion</title><p>The results of our study reveal lower BUA value in the schizophrenic patient group while these patients are young. The prevalence of low bone mass and severe low bone mass showed similar changes when compared with community populations from the same geographical area and from Kinmen Island, which is in a different geographical location. The geography- related effect can be ruled out in this study. Yuli town is in a rural area in the east part of Taiwan. Healthier young people move to the cities for work. For this reason, the sample size of the 20&#x02013;29 and the 30&#x02013;39 year old group is small in the community population group. This is also the reason of higher osteoporosis prevalence in the 20&#x02013;29 year-old male group.</p><p>Poorer bone mass in psychiatric patients has been reported in many literatures[<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. Since it can be seen even in the age group 20&#x02013;29 years, inadequate peak bone mass build or accelerated bone absorption is the possible cause of low bone mass. Reported risk factors for the increased prevalence of osteoporosis in psychiatric patients include polydipsia[<xref ref-type="bibr" rid="B24">24</xref>], the use of neuroleptics [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>] and the resulting hyperprolactinemia[<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B32">32</xref>], heavy smoking[<xref ref-type="bibr" rid="B33">33</xref>], poor diet, drug and alcohol abuse[<xref ref-type="bibr" rid="B34">34</xref>], and lack of exercise[<xref ref-type="bibr" rid="B30">30</xref>]. These factors were supposed to accelerate bone absorption. The onset of schizophrenia typically occurs during adolescence and young adulthood. Therefore, the use of antipsychotic medications with their attendant metabolic changes also begins at the same stage. Lifestyle changes also begin at about the same period. Each of these factors or a combined effect of these factors may inhibit the build-up of peak bone mass or accelerate bone loss, and may be the reason for low BUA values in age groups younger than 50 years.</p><p>A rapid decrease of bone mass and an increase of osteoporosis during the menopausal transition are reported in the community female population[<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. However, the trend test of BUA value in female schizophrenic patients cannot show the transition effect in our study. Hyperprolactinemia caused by the medication of many kinds of neuroleptics was suspected to suppress gonadotropins and gonadal hormones[<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. Low BMD values and hypogonadism was reported in young schizophrenic women with hyperprolactinemia who were treated with prolactin-raising antipsychotics[<xref ref-type="bibr" rid="B39">39</xref>]. Effect of decrease of gonadotropin on bone mass during menopausal transition in female schizophrenic patients may be irrelevant for female subjects in the community population. Further study is necessary to explain this.</p><p>The BUA value keeps relatively stable while aging, as shown in trend analysis. In the generalized linear model, BUA increased significantly with age increase. Aging is not a risk factor of poor bone mass in schizophrenic patient group in our study, and is a protective factor as the statistical result. Aging has been reported to be a risk factor of osteopenia in psychiatric patients treated with prolactin-elevating antipsychotics.[<xref ref-type="bibr" rid="B40">40</xref>] Our study does not include antipsychotics used to treat these patients. Classic neuroleptics were reported to cause hyperprolactinemia and an increased prevalence of osteoporosis than atypical neuroleptics [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. However, some atypical neuroleptic agents are reported to produce either the same or more pronounced hyperprolactinemia[<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. Interaction between aging and prolactin-elevating antipsychotics may exist. Study is necessary to explore the effect of aging on schizophrenic patients and to explore whether aging is a protective factor.</p><p>The chronic schizophrenic patient may also have several of the risk factors for osteoporosis-related fractures, commonly including unsteady gait, decreased physical activity and the use of sedative medications and low cognitive function. Residents of a long-term care unit are at a higher risk of osteoporotic fractures due to one or more of following risk factors: advanced age, poor physical function, low muscle strength, decreased cognition, dementia, poor nutrition and the use of certain medications.[<xref ref-type="bibr" rid="B4">4</xref>] The process of accelerated osteoporosis in schizophrenic patients needs to be explored and may be prevented or changed to preserve bone mass in these patients.</p></sec><sec><title>Conclusion</title><p>In this study, schizophrenic patients have lower BUA values since they are young when compared with the community population. Aging and menopausal transition effect on bone mass in the general female population cannot be seen in the schizophrenic patient group. The bone mass distribution of schizophrenic patients is different from that of the community population. This is a cross-sectional study, and does not include the information of sex hormone, bone metabolism related hormones, the type of antipsychotic medication used and bone turnover markers is its limitation. Use of ultrasonographic assessments instead of DXA scans and the assessment of bone mass at only one location is another limitation of this survey. Further studies are necessary to clarify the hormonal changes, bony metabolism and effects of medication on bone mass characteristics in schizophrenic patients. Prospective study begins from the onset of schizophrenia may be also necessary. Once the cause and effect relationships are clearer, intervention may be used to either prevent or delay the onset of osteoporosis in these patients.</p></sec><sec><title>Competing interests</title><p>The whole study is funded by research budget of Yuli Veterans Hospital for supporting and encouraging staff to perform study related to medicine. Otherwise, there are no other competing interests.</p></sec><sec><title>Authors' contributions</title><p>JHR conducted and performed the whole project. NPY carried the data analysis. CMC and CYL confirmed the schizophrenia diagnosis. THL sampled the schizophrenic patients within all inpatient in Yuli Veterans Hospital and arranged and recorded result and arranged the schedule of ultrasound densitometer. PC designed and supervised the whole project.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2474/10/1/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Thanks for the grant support from Yuli Veterans Hospital. Thanks to all the nursing staff inthe ward of Department of Psychiatry of Yuli Veterans Hospital for helping and accompanying these patients while they received calcaneal ultrasonometer examination. Thanks to Katherine Diane Cox for the copyediting of the paper.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>SL</given-names></name><name><surname>Slemenda</surname><given-names>CW</given-names></name><name><surname>Johnston</surname><given-names>CC</given-names><suffix>Jr</suffix></name></person-group><article-title>Age and bone mass as predictors of fracture in a prospective study</article-title><source>J Clin Invest</source><year>1988</year><volume>81</volume><fpage>1804</fpage><lpage>1809</lpage><pub-id pub-id-type="pmid">3384952</pub-id><pub-id pub-id-type="doi">10.1172/JCI113523</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><collab>Consensus conference</collab></person-group><article-title>Osteoporosis</article-title><source>JAMA</source><year>1984</year><volume>252</volume><fpage>799</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">6748181</pub-id><pub-id pub-id-type="doi">10.1001/jama.252.6.799</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Rubin</surname><given-names>SM</given-names></name><name><surname>Black</surname><given-names>D</given-names></name></person-group><article-title>The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen</article-title><source>Clin Orthop Relat Res</source><year>1990</year><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">2302881</pub-id></citation></ref><ref id="B4"><citation citation-type="other"><article-title>NIH Consensus Statement. Osteoporosis prevention, diagnosis, and therapy</article-title><source>(Statement NC ed)</source><volume>17</volume><fpage>1</fpage><lpage>36</lpage></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rigotti</surname><given-names>NA</given-names></name><name><surname>Neer</surname><given-names>RM</given-names></name><name><surname>Jameson</surname><given-names>L</given-names></name></person-group><article-title>Osteopenia and bone fractures in a man with anorexia nervosa and hypogonadism</article-title><source>JAMA</source><year>1986</year><volume>256</volume><fpage>385</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">3723727</pub-id><pub-id pub-id-type="doi">10.1001/jama.256.3.385</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biller</surname><given-names>BM</given-names></name><name><surname>Saxe</surname><given-names>V</given-names></name><name><surname>Herzog</surname><given-names>DB</given-names></name><name><surname>Rosenthal</surname><given-names>DI</given-names></name><name><surname>Holzman</surname><given-names>S</given-names></name><name><surname>Klibanski</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa</article-title><source>J Clin Endocrinol Metab</source><year>1989</year><volume>68</volume><fpage>548</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">2493036</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>MM</given-names></name><name><surname>Halmi</surname><given-names>KA</given-names></name></person-group><article-title>Relationship of bone density to estradiol and cortisol in anorexia nervosa and bulimia</article-title><source>Psychiatry Res</source><year>1989</year><volume>29</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">2772096</pub-id><pub-id pub-id-type="doi">10.1016/0165-1781(89)90190-X</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salisbury</surname><given-names>JJ</given-names></name><name><surname>Mitchell</surname><given-names>JE</given-names></name></person-group><article-title>Bone mineral density and anorexia nervosa in women</article-title><source>Am J Psychiatry</source><year>1991</year><volume>148</volume><fpage>768</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">2035719</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halbreich</surname><given-names>U</given-names></name><name><surname>Rojansky</surname><given-names>N</given-names></name><name><surname>Palter</surname><given-names>S</given-names></name><name><surname>Hreshchyshyn</surname><given-names>M</given-names></name><name><surname>Kreeger</surname><given-names>J</given-names></name><name><surname>Bakhai</surname><given-names>Y</given-names></name><name><surname>Rosan</surname><given-names>R</given-names></name></person-group><article-title>Decreased bone mineral density in medicated psychiatric patients</article-title><source>Psychosom Med</source><year>1995</year><volume>57</volume><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">8552740</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>G</given-names></name><name><surname>Friedman</surname><given-names>RH</given-names></name><name><surname>Verghese</surname><given-names>C</given-names></name><name><surname>de Leon</surname><given-names>J</given-names></name></person-group><article-title>Osteoporosis and schizophrenia: can we limit known risk factors?</article-title><source>Biol Psychiatry</source><year>1995</year><volume>38</volume><fpage>131</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">7578648</pub-id><pub-id pub-id-type="doi">10.1016/0006-3223(95)00062-L</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenspan</surname><given-names>SL</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>PD</given-names></name><name><surname>Orwoll</surname><given-names>ES</given-names></name></person-group><article-title>Clinical performance of a highly portable, scanning calcaneal ultrasonometer</article-title><source>Osteoporos Int</source><year>2001</year><volume>12</volume><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">11444088</pub-id><pub-id pub-id-type="doi">10.1007/s001980170108</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meszaros</surname><given-names>S</given-names></name><name><surname>Toth</surname><given-names>E</given-names></name><name><surname>Ferencz</surname><given-names>V</given-names></name><name><surname>Csupor</surname><given-names>E</given-names></name><name><surname>Hosszu</surname><given-names>E</given-names></name><name><surname>Horvath</surname><given-names>C</given-names></name></person-group><article-title>Calcaneous quantitative ultrasound measurements predicts vertebral fractures in idiopathic male osteoporosis</article-title><source>Joint Bone Spine</source><year>2007</year><volume>74</volume><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">17197223</pub-id><pub-id pub-id-type="doi">10.1016/j.jbspin.2006.04.008</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonnelli</surname><given-names>S</given-names></name><name><surname>Cepollaro</surname><given-names>C</given-names></name></person-group><article-title>The use of ultrasound in the assessment of bone status</article-title><source>J Endocrinol Invest</source><year>2002</year><volume>25</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">12030613</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>ML</given-names></name><name><surname>Blake</surname><given-names>GM</given-names></name><name><surname>Fogelman</surname><given-names>I</given-names></name></person-group><article-title>Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis</article-title><source>J Bone Miner Res</source><year>2001</year><volume>16</volume><fpage>406</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">11204441</pub-id><pub-id pub-id-type="doi">10.1359/jbmr.2001.16.2.406</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>ML</given-names></name><name><surname>Blake</surname><given-names>GM</given-names></name><name><surname>Fogelman</surname><given-names>I</given-names></name></person-group><article-title>A comparison of fracture discrimination using calcaneal quantitative ultrasound and dual X-ray absorptiometry in women with a history of fracture at sites other than the spine and hip</article-title><source>Calcif Tissue Int</source><year>2002</year><volume>71</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">12154392</pub-id><pub-id pub-id-type="doi">10.1007/s00223-001-2074-y</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cetin</surname><given-names>A</given-names></name><name><surname>Erturk</surname><given-names>H</given-names></name><name><surname>Celiker</surname><given-names>R</given-names></name><name><surname>Sivri</surname><given-names>A</given-names></name><name><surname>Hascelik</surname><given-names>Z</given-names></name></person-group><article-title>The role of quantitative ultrasound in predicting osteoporosis defined by dual X-ray absorptiometry</article-title><source>Rheumatol Int</source><year>2001</year><volume>20</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">11269533</pub-id><pub-id pub-id-type="doi">10.1007/PL00006857</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dane</surname><given-names>C</given-names></name><name><surname>Dane</surname><given-names>B</given-names></name><name><surname>Cetin</surname><given-names>A</given-names></name><name><surname>Erginbas</surname><given-names>M</given-names></name></person-group><article-title>The role of quantitative ultrasound in predicting osteoporosis defined by dual-energy X-ray absorptiometry in pre- and postmenopausal women</article-title><source>Climacteric</source><year>2008</year><volume>11</volume><fpage>296</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">18645695</pub-id><pub-id pub-id-type="doi">10.1080/13697130802178471</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulleman</surname><given-names>D</given-names></name><name><surname>Legroux-Gerot</surname><given-names>I</given-names></name><name><surname>Duquesnoy</surname><given-names>B</given-names></name><name><surname>Marchandise</surname><given-names>X</given-names></name><name><surname>Delcambre</surname><given-names>B</given-names></name><name><surname>Cortet</surname><given-names>B</given-names></name></person-group><article-title>Quantitative ultrasound of bone in male osteoporosis</article-title><source>Osteoporos Int</source><year>2002</year><volume>13</volume><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">12086349</pub-id><pub-id pub-id-type="doi">10.1007/s001980200044</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pocock</surname><given-names>NA</given-names></name><name><surname>Culton</surname><given-names>NL</given-names></name><name><surname>Gilbert</surname><given-names>GR</given-names></name><name><surname>Hoy</surname><given-names>ML</given-names></name><name><surname>Babicheva</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Freund</surname><given-names>J</given-names></name></person-group><article-title>Potential roles for quantitative ultrasound in the management of osteoporosis</article-title><source>Med J Aust</source><year>2000</year><volume>173</volume><fpage>355</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">11062790</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hans</surname><given-names>D</given-names></name><name><surname>Fuerst</surname><given-names>T</given-names></name><name><surname>Lang</surname><given-names>T</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Genant</surname><given-names>HK</given-names></name><name><surname>Gluer</surname><given-names>C</given-names></name></person-group><article-title>How can we measure bone quality?</article-title><source>Baillieres Clin Rheumatol</source><year>1997</year><volume>11</volume><fpage>495</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">9367034</pub-id><pub-id pub-id-type="doi">10.1016/S0950-3579(97)80017-9</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herd</surname><given-names>RJ</given-names></name><name><surname>Blake</surname><given-names>GM</given-names></name><name><surname>Miller</surname><given-names>CG</given-names></name><name><surname>Parker</surname><given-names>JC</given-names></name><name><surname>Fogelman</surname><given-names>I</given-names></name></person-group><article-title>The ultrasonic assessment of osteopenia as defined by dual X-ray absorptiometry</article-title><source>Br J Radiol</source><year>1994</year><volume>67</volume><fpage>631</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">8061996</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>NP</given-names></name><name><surname>Jen</surname><given-names>I</given-names></name><name><surname>Chuang</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Chou</surname><given-names>P</given-names></name></person-group><article-title>Screening for low bone mass with quantitative ultrasonography in a community without dual-energy X-ray absorptiometry: population-based survey</article-title><source>BMC Musculoskelet Disord</source><year>2006</year><volume>7</volume><fpage>24</fpage><pub-id pub-id-type="pmid">16526954</pub-id><pub-id pub-id-type="doi">10.1186/1471-2474-7-24</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>JM</given-names></name><name><surname>Lehman</surname><given-names>D</given-names></name></person-group><article-title>Bone mineral density in male schizophrenia patients: a review</article-title><source>Ann Clin Psychiatry</source><year>2006</year><volume>18</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">16517452</pub-id><pub-id pub-id-type="doi">10.1080/10401230500464687</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delva</surname><given-names>NJ</given-names></name><name><surname>Crammer</surname><given-names>JL</given-names></name><name><surname>Jarzylo</surname><given-names>SV</given-names></name><name><surname>Lawson</surname><given-names>JS</given-names></name><name><surname>Owen</surname><given-names>JA</given-names></name><name><surname>Sribney</surname><given-names>M</given-names></name><name><surname>Weir</surname><given-names>BJ</given-names></name><name><surname>Yendt</surname><given-names>ER</given-names></name></person-group><article-title>Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia</article-title><source>Biol Psychiatry</source><year>1989</year><volume>26</volume><fpage>781</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">2590692</pub-id><pub-id pub-id-type="doi">10.1016/0006-3223(89)90119-4</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rojansky</surname><given-names>N</given-names></name><name><surname>Halbreich</surname><given-names>U</given-names></name><name><surname>Rosan</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Hreshchyshyn</surname><given-names>M</given-names></name></person-group><article-title>Hormonally-related osteoporosis in chronic psychiatric patients</article-title><source>Neuroendocrin Letters</source><year>1990</year><volume>12</volume><fpage>304</fpage></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutsuma</surname><given-names>K</given-names></name></person-group><article-title>[Bone histomorphometric study of the ilium in psychiatric patients with longterm administration of anti-psychiatric drugs]</article-title><source>Nippon Seikeigeka Gakkai Zasshi</source><year>1993</year><volume>67</volume><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">8409629</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacro</surname><given-names>JP</given-names></name><name><surname>Jeste</surname><given-names>DV</given-names></name></person-group><article-title>Physical comorbidity and polypharmacy in older psychiatric patients</article-title><source>Biol Psychiatry</source><year>1994</year><volume>36</volume><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">7948452</pub-id><pub-id pub-id-type="doi">10.1016/0006-3223(94)91220-3</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klibanski</surname><given-names>A</given-names></name><name><surname>Neer</surname><given-names>RM</given-names></name><name><surname>Beitins</surname><given-names>IZ</given-names></name><name><surname>Ridgway</surname><given-names>EC</given-names></name><name><surname>Zervas</surname><given-names>NT</given-names></name><name><surname>McArthur</surname><given-names>JW</given-names></name></person-group><article-title>Decreased bone density in hyperprolactinemic women</article-title><source>N Engl J Med</source><year>1980</year><volume>303</volume><fpage>1511</fpage><lpage>1514</lpage><pub-id pub-id-type="pmid">7432421</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schlechte</surname><given-names>JA</given-names></name><name><surname>Sherman</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name></person-group><article-title>Bone density in amenorrheic women with and without hyperprolactinemia</article-title><source>J Clin Endocrinol Metab</source><year>1983</year><volume>56</volume><fpage>1120</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">6404918</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ataya</surname><given-names>K</given-names></name><name><surname>Mercado</surname><given-names>A</given-names></name><name><surname>Kartaginer</surname><given-names>J</given-names></name><name><surname>Abbasi</surname><given-names>A</given-names></name><name><surname>Moghissi</surname><given-names>KS</given-names></name></person-group><article-title>Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia</article-title><source>Fertil Steril</source><year>1988</year><volume>50</volume><fpage>876</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">2904890</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kartaginer</surname><given-names>J</given-names></name><name><surname>Ataya</surname><given-names>K</given-names></name><name><surname>Mercado</surname><given-names>A</given-names></name><name><surname>Abbasi</surname><given-names>A</given-names></name></person-group><article-title>Osteoporosis associated with neuroleptic treatment. A case report</article-title><source>J Reprod Med</source><year>1990</year><volume>35</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">1968102</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naidoo</surname><given-names>U</given-names></name><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Klibanski</surname><given-names>A</given-names></name></person-group><article-title>Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents</article-title><source>Psychoneuroendocrinology</source><year>2003</year><volume>28</volume><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">12650684</pub-id><pub-id pub-id-type="doi">10.1016/S0306-4530(02)00129-4</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Leon</surname><given-names>J</given-names></name><name><surname>Verghese</surname><given-names>C</given-names></name><name><surname>Tracy</surname><given-names>JI</given-names></name><name><surname>Josiassen</surname><given-names>RC</given-names></name><name><surname>Simpson</surname><given-names>GM</given-names></name></person-group><article-title>Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature</article-title><source>Biol Psychiatry</source><year>1994</year><volume>35</volume><fpage>408</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">8018788</pub-id><pub-id pub-id-type="doi">10.1016/0006-3223(94)90008-6</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindholm</surname><given-names>J</given-names></name><name><surname>Steiniche</surname><given-names>T</given-names></name><name><surname>Rasmussen</surname><given-names>E</given-names></name><name><surname>Thamsborg</surname><given-names>G</given-names></name><name><surname>Nielsen</surname><given-names>IO</given-names></name><name><surname>Brockstedt-Rasmussen</surname><given-names>H</given-names></name><name><surname>Storm</surname><given-names>T</given-names></name><name><surname>Hyldstrup</surname><given-names>L</given-names></name><name><surname>Schou</surname><given-names>C</given-names></name></person-group><article-title>Bone disorder in men with chronic alcoholism: a reversible disease?</article-title><source>J Clin Endocrinol Metab</source><year>1991</year><volume>73</volume><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">2045462</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sowers</surname><given-names>MR</given-names></name><name><surname>Jannausch</surname><given-names>M</given-names></name><name><surname>McConnell</surname><given-names>D</given-names></name><name><surname>Little</surname><given-names>R</given-names></name><name><surname>Greendale</surname><given-names>GA</given-names></name><name><surname>Finkelstein</surname><given-names>JS</given-names></name><name><surname>Neer</surname><given-names>RM</given-names></name><name><surname>Johnston</surname><given-names>J</given-names></name><name><surname>Ettinger</surname><given-names>B</given-names></name></person-group><article-title>Hormone predictors of bone mineral density changes during the menopausal transition</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>1261</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">16403818</pub-id><pub-id pub-id-type="doi">10.1210/jc.2005-1836</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guthrie</surname><given-names>JR</given-names></name><name><surname>Ebeling</surname><given-names>PR</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Dennerstein</surname><given-names>L</given-names></name><name><surname>Dudley</surname><given-names>EC</given-names></name><name><surname>Burger</surname><given-names>HG</given-names></name><name><surname>Wark</surname><given-names>JD</given-names></name></person-group><article-title>A prospective study of bone loss in menopausal Australian-born women</article-title><source>Osteoporos Int</source><year>1998</year><volume>8</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">9797914</pub-id><pub-id pub-id-type="doi">10.1007/s001980050066</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halbreich</surname><given-names>U</given-names></name><name><surname>Palter</surname><given-names>S</given-names></name></person-group><article-title>Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes</article-title><source>Schizophr Bull</source><year>1996</year><volume>22</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">8873295</pub-id></citation></ref><ref id="B38"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Levinson</surname><given-names>DF</given-names></name><name><surname>Simpson</surname><given-names>FM</given-names></name></person-group><source>Antipsychotic drug side effects</source><year>1987</year><publisher-name>Washington, DC: American Psychiatric Association</publisher-name></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Keane</surname><given-names>V</given-names></name><name><surname>Meaney</surname><given-names>AM</given-names></name></person-group><article-title>Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?</article-title><source>J Clin Psychopharmacol</source><year>2005</year><volume>25</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15643097</pub-id><pub-id pub-id-type="doi">10.1097/01.jcp.0000150223.31007.e0</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu-Seifert</surname><given-names>H</given-names></name><name><surname>Kinon</surname><given-names>BJ</given-names></name><name><surname>Ahl</surname><given-names>J</given-names></name><name><surname>Lamberson</surname><given-names>S</given-names></name></person-group><article-title>Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics</article-title><source>Ann N Y Acad Sci</source><year>2004</year><volume>1032</volume><fpage>297</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">15677434</pub-id><pub-id pub-id-type="doi">10.1196/annals.1314.044</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bilici</surname><given-names>M</given-names></name><name><surname>Cakirbay</surname><given-names>H</given-names></name><name><surname>Guler</surname><given-names>M</given-names></name><name><surname>Tosun</surname><given-names>M</given-names></name><name><surname>Ulgen</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>U</given-names></name></person-group><article-title>Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia</article-title><source>Int J Neurosci</source><year>2002</year><volume>112</volume><fpage>817</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">12424822</pub-id><pub-id pub-id-type="doi">10.1080/00207450290025833</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>D</given-names></name><name><surname>Liver</surname><given-names>O</given-names></name><name><surname>Mester</surname><given-names>R</given-names></name><name><surname>Rapoport</surname><given-names>M</given-names></name><name><surname>Weizman</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>M</given-names></name></person-group><article-title>Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><fpage>761</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">12934975</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>KK</given-names></name></person-group><article-title>Management of hyperprolactinemia in patients receiving antipsychotics</article-title><source>CNS Spectr</source><year>2004</year><volume>9</volume><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15303078</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamner</surname><given-names>M</given-names></name></person-group><article-title>The effects of atypical antipsychotics on serum prolactin levels</article-title><source>Ann Clin Psychiatry</source><year>2002</year><volume>14</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">12585566</pub-id></citation></ref></ref-list></back></article>